

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUYI INTERNATIONAL PHARMACEUTICAL COMPANY LIMITED

武夷國際藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules.

The Board wishes to inform the shareholders of the Company and potential investors that it is presently expected that the results of the Group for the financial year ended 31 December 2008 will be affected.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Wuyi International Pharmaceutical Company Limited (the “Company”, together with its subsidiaries, the “Group”) pursuant to Rule 13.09(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The board of directors of the Company (the “Board”) wishes to inform the shareholders of the Company and potential investors that having assessed the currently available information, the Group is likely to record a moderate decline in net profit for the year ended 31 December 2008 as compared with a net profit for that of last year due to the unprecedented credit and the volatility in the economy. The Board considers that the Group’s financial performance has been affected by: (i) expected moderate decline in sales due to current adverse macro-economic conditions and substantial downturn of the global financial markets; and (ii) a payment of significant amount of the Enterprise Income tax by one of our major PRC subsidiaries after the expiration of tax exemption period in 2007.

As the Company is still in the process of finalizing its results for the year ended 31 December 2008, the information contained in this announcement is a preliminary estimate given by the management of the Group and is not based on any figures nor information that has been audited or reviewed by the Company’s auditor.

Despite the lower profit for the year ended 31 December 2008, the Board considers that the Group's overall financial position is still healthy and the Board remains positive on the long term prospect of the Group.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Wuyi International Pharmaceutical Company Limited
Lin Ou Wen
Chairman and Chief Executive Officer

Hong Kong, 9 March 2009

As at the date of this announcement, the Board comprises 3 Executive Directors, namely Mr. Lin Ou Wen (Chairman), Mr. Lin Qing Ping and Mr. Xu Chao Hui, 2 Non-executive Directors, namely Mr. Tang Bin and Mr. John Yang Wang, and 3 Independent Non-executive Directors, namely, Mr. Goh Jin Hian, Mr. Liu Jun and Mr. Lam Yat Cheong.